Arcus Biosciences Inc (RCUS)
Quick ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | US$ in thousands | 127,000 | 184,000 | 230,000 | 238,000 | 206,000 | 218,000 | 273,000 | 549,000 | 148,000 | 179,432 | 320,482 | 390,260 | 173,415 | 221,849 | 285,185 | 67,326 | 57,937 | 78,992 | 76,068 | 68,499 |
Short-term investments | US$ in thousands | 632,000 | 615,000 | 700,000 | 716,000 | 803,000 | 831,135 | 900,147 | 664,751 | 351,394 | 345,210 | 400,530 | 436,666 | 555,231 | 560,583 | 177,288 | 90,540 | 130,333 | 111,997 | 148,330 | 173,436 |
Receivables | US$ in thousands | 4,000 | 4,000 | 35,000 | 36,000 | 43,000 | 29,944 | 38,916 | 32,008 | 746,762 | 2,818 | 2,724 | 5,953 | 1,592 | 372 | 239 | — | 251 | 0 | 62 | 0 |
Total current liabilities | US$ in thousands | 184,000 | 200,000 | 180,000 | 179,000 | 193,000 | 177,176 | 164,024 | 161,254 | 166,000 | 142,866 | 130,370 | 132,055 | 121,669 | 162,871 | 40,025 | 21,004 | 22,706 | 21,057 | 26,513 | 19,003 |
Quick ratio | 4.15 | 4.02 | 5.36 | 5.53 | 5.45 | 6.09 | 7.39 | 7.73 | 7.51 | 3.69 | 5.55 | 6.31 | 6.00 | 4.81 | 11.56 | 7.52 | 8.30 | 9.07 | 8.47 | 12.73 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($127,000K
+ $632,000K
+ $4,000K)
÷ $184,000K
= 4.15
The quick ratio, also known as the acid-test ratio, measures a company's ability to meet its short-term obligations with its most liquid assets, excluding inventory. Arcus Biosciences Inc's quick ratio has been consistently strong over the past eight quarters, ranging from 4.41 to 7.84.
The upward trend from Q1 2022 to Q2 2023 indicates an improving ability to cover its short-term liabilities with liquid assets. This suggests a favorable liquidity position for the company, with higher values indicating greater ability to quickly pay off current obligations.
A quick ratio above 1 generally indicates that a company can meet its short-term liabilities with ease, and Arcus Biosciences Inc significantly exceeds this threshold in all periods analyzed. However, it's important to note that an extremely high quick ratio may also suggest an inefficient use of resources, such as excessive cash holdings.
Overall, Arcus Biosciences Inc's consistently strong quick ratio reflects a healthy liquidity position, signaling its ability to handle short-term financial obligations effectively.
Peer comparison
Dec 31, 2023